Wang Yongjun
Wang Yongjun is a renowned Chinese clinical scientist and a leading figure in the field of stroke research. He has made significant contributions over four decades, particularly in the areas of ischemic stroke treatment and secondary prevention strategies. As the founder and president of the Chinese Stroke Association and the director of the Neurology Division of the Chinese Medical Association, Wang has spearheaded major clinical trials, including the influential CHANCE and TRACE studies. His groundbreaking work has reshaped global stroke treatment guidelines and earned him numerous accolades, including the prestigious William M. Feinberg Stroke Excellence Award in 2025, marking the first time an Asian scientist has received this honor.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| China | 2 | 5.00 | 0.13% | +0% | 1,402,112,000 | 1,848,533 | $14,000,000 | 18,457$ |
| Totals | 2 | 1,402,112,000 | 1,848,533 | $14,000,000 | 18,457$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
China:
Wang Yongjun contributed to the meeting discussions.
5
China:
Wang Yongjun spoke at the meeting.
5
China:
Wang Yongjun views the establishment of 1000 rural museums as a way to connect and preserve rural culture in Zhejiang.
8
China:
Wang Yongjun was awarded the 'William M. Feinberg Stroke Excellence Award' for his global contributions in the field of stroke research and clinical practice.
9